INVIVYD, INC. Shareholders' Equity
INVIVYD, INC. (IVVD) had Shareholders' Equity of $181.08 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-13
- 2026-06-30: Stockholders' Equity Attributable to Parent $181.08M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $203.05M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $241.54M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $93.07M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $181.08M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $203.05M 10-Q · filed 2026-08-13 |
| 2025-12-31 | $241.54M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $93.07M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $42.79M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $54.15M 10-Q · filed 2026-08-13 |
| 2024-12-31 | $67.54M 10-Q · filed 2026-08-13 |
| 2024-09-30 | $83.16M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $140.64M 10-Q · filed 2025-11-06 |
| 2024-03-31 | $178.50M 10-Q · filed 2025-11-06 |
| 2023-12-31 | $177.47M 10-K · filed 2026-03-05 |
| 2023-09-30 | $246.50M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $281.56M 10-Q · filed 2024-11-14 |
| 2023-03-31 | $326.75M 10-Q · filed 2024-11-14 |
| 2022-12-31 | $355.97M 10-K · filed 2025-03-20 |
| 2022-09-30 | $377.44M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $414.84M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $459.39M 10-Q · filed 2023-11-09 |
| 2021-12-31 | $558.02M 10-K · filed 2024-03-28 |
| 2021-09-30 | $633.21M 10-Q · filed 2022-11-10 |
| 2021-06-30 | -$144.62M 10-Q · filed 2022-11-10 |
| 2021-03-31 | -$103.36M 10-Q · filed 2022-11-10 |
| 2020-12-31 | -$65.25M 8-K · filed 2024-02-09 |
| 2020-09-30 | -$48.18M 10-Q · filed 2021-11-15 |
| 2020-06-30 | -$98.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |